Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Biotechnology company developing sustainable therapies and a phage discovery platform for infectious diseases in human health and agriculture.
Based in South San Francisco, California, EpiBiome is a biotechnology company that engineers microbiomes and develops sustainable bacteriophage therapies to combat infectious diseases in humans and agriculture as alternatives to traditional antibiotics. To achieve this, the organization utilizes a high-throughput automated phage discovery platform combining next-generation sequencing, bioinformatics, machine learning, and directed evolution to target antibiotic-resistant pathogens. After graduating from the inaugural class of the Illumina Accelerator and winning a Johnson & Johnson JLABS challenge, the enterprise secured $6 million in Series A financing. This initial funding round was backed by prominent institutional investors including Viking Global Investors, Matrix Capital Management, and Alexandria Venture Investments. In July 2018, the company and its proprietary phage discovery platform were officially acquired by Locus Biosciences. EpiBiome was founded in 2013 by Aeron Hammack, Christina Tsai, and Nick Conley.
EpiBiome has raised $7.0M across 2 funding rounds.
EpiBiome has raised $7.0M in total across 2 funding rounds.
EpiBiome has raised $7.0M in total across 2 funding rounds.
EpiBiome's investors include Silicon Valley Bank, Alexandria Venture Investments, CRCM Ventures, Matrix Capital Management, Benard Joseph Yu, Viking Global Investors.
EpiBiome has raised $7.0M across 2 funding rounds. Most recently, it raised $1.0M Debt in June 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 23, 2016 | $1M Debt Financing | Silicon Valley Bank | — | Announced |
| Feb 4, 2016 | $6M Series A | — | Alexandria Venture Investments, CRCM Ventures, Matrix Capital Management, Benard Joseph YU, Viking Global Investors | Announced |